Sign up

Experience where it matters.

For more than 35 years, healthcare providers and people with rare bleeding disordersa have trusted NovoSeven® RT. It’s the first recombinant factor VIIa (rFVIIa) that is:

Checkmark icon

Indicated for people of all ages with hemophilia A or B with inhibitors, congenital FVII deficiency, and Glanzmann's thrombasthenia when platelets don’t work, and adults with acquired hemophilia.

Checkmark icon

Approved for use before, during, and after surgery and procedures

Checkmark icon

The only rFVIIa used for breakthrough bleeds in the Hemlibra® pivotal clinical trials

Take a Closer Look

aCompassionate use, also known as expanded access, began enrolling in 1988; FDA approval received in 1999 for people with hemophilia A or B with inhibitors.

Krystal and her son Dallas, who lives with
Glanzmann’s thrombasthenia (GT) with resistance
to platelets and uses NovoSeven® RT.

Experience where it matters.

For more than 35 years, healthcare providers and people with rare bleeding disordersa have trusted NovoSeven® RT. It’s the first recombinant factor VIIa (rFVIIa) that is:

  • Indicated for people of all ages with hemophilia A or B with inhibitors, congenital FVII deficiency, and Glanzmann's thrombasthenia when platelets don’t work, and adults with acquired hemophilia.
  • Approved for use before, during, and after surgery and procedures
  • The only rFVIIa used for breakthrough bleeds in the Hemlibra® pivotal clinical trials

Take a Closer Look

aCompassionate use, also known as expanded access, began enrolling in 1988; FDA approval received in 1999 for people with hemophilia A or B with inhibitors.

Krystal and her son Dallas, who lives with Glanzmann’s thrombasthenia (GT) with resistance to platelets and uses NovoSeven® RT.

Is NovoSeven® RT right for you?

See how NovoSeven® RT can help you control bleeds related to:

Hemophilia A with inhibitors

Hemophilia B with inhibitors

Factor VII deficiency

Glanzmann's thrombasthenia when platelets don't work

Acquired hemophilia

Syringe and vials of NovoSeven® RT (Coagulation Factor VIIa [Recombinant])

Safety profile with proven experience.

NovoSeven® RT is designed with your safety in mind. It’s the only rFVIIa used for breakthrough bleeds in the Hemlibra pivotal clinical trials.

Studies also show it has a low rate of thrombotic adverse events (blood clots). The most common and serious side effects are blood clots.

View safety information

Joseph lives with hemophilia B with an inhibitor and Taylor lives with FVIId

Your treatment, your way.

Your treatment should accommodate your lifestyle—take it from people who choose NovoSeven® RT. Hear from others with rare bleeding disorders to learn what makes this treatment the right choice for them.

Hear their stories

Hemophilia Community Liaisons for NovoSeven® RT

How can we help?

Novo Nordisk Rare Blood Community Liaisons (RBCLs) are here to answer your questions about NovoSeven® RT and connect you with resources to help you manage your bleeding disorder.

Connect with your RBCL

Stay prepared for bleeds

Did you know that identifying bleeds quickly is important? Learn the signs and symptoms of bleeds so you can identify them when and where they happen.

Identifying Bleeds

Explore Educational Resources

New to NovoSeven® RT?

Here’s how to get started:

New to NovoSeven® RT? Here’s how to get started:

I have just been prescribed NovoSeven® RT.

Let’s Get Started

I am considering NovoSeven® RT.

See the Details

Selected Important Safety Information

What is the most important information I should know about NovoSeven® RT?

NovoSeven® RT may cause serious side effects, including:

  • Serious blood clots that form in veins and arteries with the use of NovoSeven® RT have been reported
  • Your healthcare provider should discuss the risks and explain the signs and symptoms of blood clots to you. Some signs of a blood clot may include pain, swelling, warmth, redness, or a lump in your legs or arms, chest pain, shortness of breath, or sudden severe headache and/or loss of consciousness or function
  • Your healthcare provider should monitor you for blood clots during treatment with NovoSeven® RT

What is NovoSeven® RT?

NovoSeven® RT (coagulation Factor VIIa, recombinant) is an injectable medicine used for:

  • Treatment of bleeding and prevention of bleeding for surgeries and procedures in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and Glanzmann’s thrombasthenia with a decreased or absent response to platelet transfusions
  • Treatment of bleeding and prevention of bleeding for surgeries and procedures in adults with acquired hemophilia

Important Safety Information

What is the most important information I should know about NovoSeven® RT?

NovoSeven® RT may cause serious side effects, including:

  • Serious blood clots that form in veins and arteries with the use of NovoSeven® RT have been reported
  • Your healthcare provider should discuss the risks and explain the signs and symptoms of blood clots to you. Some signs of a blood clot may include pain, swelling, warmth, redness, or a lump in your legs or arms, chest pain, shortness of breath, or sudden severe headache and/or loss of consciousness or function
  • Your healthcare provider should monitor you for blood clots during treatment with NovoSeven® RT
  • You should not use NovoSeven® RT if you have ever had allergic (hypersensitivity) reactions, including severe, whole body reactions (anaphylaxis) to NovoSeven® RT, any of its ingredients, or mice, hamsters, or cows. Signs of allergic reaction include shortness of breath, rash, itching (pruritus), redness of the skin (erythema), or fainting/dizziness

What should I tell my healthcare provider before using NovoSeven® RT?

  • Tell your healthcare provider if you have any of the following, as these may increase your risk of blood clots:
    • congenital hemophilia and are also receiving treatment with aPCCs (activated prothrombin complex concentrates)
    • are an older patient particularly with acquired hemophilia and receiving other agents to stop bleeding
    • history of heart or blood vessel diseases
  • Tell your healthcare provider and pharmacist about all the medicines you take, including all prescription and non-prescription medicines, such as over-the-counter medicines, supplements, or herbal remedies

What are the possible side effects of NovoSeven® RT?

  • The most common and serious side effects are blood clots
  • Tell your healthcare provider about any side effects that bother you or do not go away, and seek medical help right away if you have signs of a blood clot or allergic reaction

Please click here for Prescribing Information